Compounded GLP-1 medications are not FDA-approved products
Effects of retatrutide on body composition in people with type 2 diabetes
Estoy dispuesto a comprometerme con un plan de mantenimiento sin los GLP1
Retatrutide is Eli Lillys once-weekly injectable triple agonist (GLP-1, GIP, and glucagon receptors) still working through Phase 3 trials, with the headline TRIUMPH-4 readout showing roughly 28.7% body-weight reduction at the 12 mg dose over 68 weeks
While formal pharmacokinetic studies of GLP-1RA co-administration with these IBD drugs have not been conducted, clinicians should monitor for unexplained changes in therapeutic response, particularly during GLP-1RA initiation and dose escalation, and consider staggering oral medications when feasible
Fiber increases SCFAs, nourishes Akkermansia and other beneficial microbes, and prevents the metabolic stagnation seen in some GLP-1 users